NCT05733611View on ClinicalTrials.gov

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 29, 2023

Primary Completion Date

January 1, 2027

Study Completion Date

March 1, 2027

Conditions
Refractory Metastatic Colorectal CancerpMMRMSS
Interventions
BIOLOGICAL

RP2

Genetically modified herpes simplex type 1 virus

BIOLOGICAL

RP3

Genetically modified herpes simplex type 1 virus

BIOLOGICAL

atezolizumab

anti-PD-L1 monoclonal antibody

BIOLOGICAL

bevacizumab

anti-VEGF therapy

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Replimune Inc.

INDUSTRY